Timothy W. Mullett named chair of the Commission on Cancer of the American College of Surgeons

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cardiothoracic surgeon Timothy W. Mullett, medical director of the Markey Cancer Center Affiliate Network, was named chair of the Commission on Cancer of the American College of Surgeons.

Mullett has been serving as the chair-elect of the CoC for the past year.

Mullett is a surgical oncologist who specializes in the treatment of lung cancer. Although he began his career at the University of Kentucky as a cardiothoracic surgeon treating heart issues, he soon shifted his professional focus to treating lung cancer. Today, he is a co-leader and principal investigator of the Kentucky LEADS Collaborative to improve lung cancer survival.

In addition to his work in lung cancer research, Mullett serves as the chair of UK’s cancer committee and the medical director of the Markey Cancer Center Research Network, a collaborative network that conducts high-priority trials, including therapeutic oncology trials and interventional and non-interventional studies for community centers.

In his role as chair, Mullett will serve as the spokesperson for oncology issues addressed by the organization, identify priorities for the CoC and National Cancer Database.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login